Heron Neutron Medical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	10.31	-	0.24	-
Cost of Revenue	36.09	3.59	0.11	-
Gross Profit	-25.78	-3.59	0.13	-
Selling, General & Admin	186.68	82.02	44.79	36.23
Research & Development	321.87	173.39	84.85	51.57
Operating Expenses	508.54	255.41	129.64	87.8
Operating Income	-534.32	-259	-129.51	-87.8
Interest Expense	-0.89	-0.18	-0.24	-0.28
Interest & Investment Income	46.19	5.72	2.12	0.1
Currency Exchange Gain (Loss)	-	0.43	-0.19	0.48
Other Non Operating Income (Expenses)	7.36	-	0.94	-
EBT Excluding Unusual Items	-481.67	-253.03	-126.88	-87.49
Gain (Loss) on Sale of Investments	-	-	0.49	1.31
Gain (Loss) on Sale of Assets	-	-7.05	-	-
Pretax Income	-481.67	-260.08	-126.39	-86.18
Net Income	-481.67	-260.08	-126.39	-86.18
Net Income to Common	-481.67	-260.08	-126.39	-86.18
Shares Outstanding (Basic)	146	128	107	76
Shares Outstanding (Diluted)	146	128	107	76
Shares Change (YoY)	14.06%	19.11%	40.45%	-
EPS (Basic)	-3.31	-2.04	-1.18	-1.13
EPS (Diluted)	-3.31	-2.04	-1.18	-1.13
Free Cash Flow	-512.21	-302.19	-110.76	-173.14
Free Cash Flow Per Share	-3.52	-2.37	-1.03	-2.27
Gross Margin	-250.12%	-	54.20%	-
Operating Margin	-5183.58%	-	-54415.97%	-
Profit Margin	-4672.74%	-	-53105.04%	-
Free Cash Flow Margin	-4969.02%	-	-46536.13%	-
EBITDA	-494.7	-242.89	-119.36	-78.91
D&A For EBITDA	39.63	16.11	10.15	8.89
EBIT	-534.32	-259	-129.51	-87.8
Advertising Expenses	-	3.24	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.